ANNX
Annexon, Inc.
Biotechnology · Healthcare · United States
4.05
close · 2026-10-30
value
40
cheaper than peers40
quality
29
stronger fundamentals29
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 1 year ago | -15.4% | 51 |
| earnings yield, 1 year ago | -24.9% | 51 |
| earnings yield, 2 years ago | -43.7% | 48 |
| cash flow yield, 3 years ago | -16.0% | 48 |
| cash flow yield, 2 years ago | -15.8% | 47 |
| earnings yield, 3 years ago | -64.2% | 46 |
| earnings yield, latest year | -33.1% | 45 |
| cash flow yield, latest year | -24.3% | 40 |
| price to book | 3.80× | 35 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 0.0% | 50 |
| debt to equity | 12.4% | 38 |
| return on equity | -87.6% | 32 |
3 of 4 measures available
Facts
| market cap | $768M |
| free cash flow | -$107.3M |
| employees | 93 |
| first trade | 2020-07-24 |
| next earnings | 2026-08-12 |
| fundamentals updated | 2026-08-12 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.34 | -1.01 | -1.77 | -2.60 |
| free cash flow | -$186.5M | -$118.0M | -$121.3M | -$122.8M |
| net income | -$206.7M | -$138.2M | -$134.2M | -$141.9M |
| revenue | $0 | $0 | $0 | $0 |